Recurrent structural and numerical chromosomal aberration and molecular markers, such as Fms like tyrosine kinase 3 (FLT3), Nucleophosmin 1 (NPM1), and DNA methyltransferase 3 alpha (DNMT3A) mutations, were proved to have an impact on AML treatment response and prognosis [6,7,8,9,10,11]. The gene discussed is FLT3; the disease is acute myeloid leukemia.